Moderna and Johnson & Johnson say clinical trial data support need for Covid vaccine boosters

- Advertisement -


  • Moderna and Johnson & Johnson COVID-19 Vaccine Booster. An FDA advisory panel is meeting this week to discuss
  • FDA published briefing document with data this week, says both companies support need for vaccine boosters
  • Moderna hopes to authorize a third shot of its vaccine for use in people over the age of 65 or with serious illnesses — just like Pfizer did.
  • Johnson & Johnson is hoping that its booster will be available to people six months after the first shot, and only two months later to people with comorbidities.

- Advertisement -

Moderna and Johnson & Johnson are pushing to approve COVID-19 vaccine boosters ahead of a key US Food and Drug Administration (FDA) advisory committee meeting later this week.

Both firms say data in briefing documents published Tuesday by the FDA show additional doses are needed.

advertisement

Moderna said the data support the use of boosters for people 18 years of age and older after receiving the second shot, citing the decreased effectiveness of the shots in preventing infection and the increased antibody levels provided by the third shots. does.

J&J is also competing to give adults a booster shot six months after the first dose, and said its clinical trial data showed that adults should also be given boosters.

- Advertisement -

The New Brunswick, New Jersey-based company also says that people who are at particularly high risk should receive a second shot two months after the first shot.

A two-day advisory advisory meeting will begin on Thursday to discuss whether companies need a booster.

Moderna is hoping its COVID-19 vaccine booster shot will receive authorization for people over the age of 65 or with serious comorbidities – as Pfizer-BioNtech received the vaccine (file image)

Johnson & Johnson is hoping to authorize a second shot of its COVID-19 vaccine six months after receipt of the first shot, or only two months for people with severe vulnerabilities to COVID (file iamge)

Johnson & Johnson is hoping to authorize a second shot of its COVID-19 vaccine six months after receipt of the first shot, or only two months for people with severe vulnerabilities to COVID (file iamge)

Currently, the Pfizer-BioNTech vaccine is the only shot with a booster dose authorized for people 65 years of age or older or who are at high risk of serious illness because of an underlying condition or their job.

Immunocompromised Americans may also be given a booster dose, as can the third shot of Moderna’s vaccine.

As of Tuesday, 7.8 million doses of the COVID-19 vaccine booster have been distributed, official data from the Centers for Disease Control and Prevention (CDC) shows.

A vast majority, 6.2 million, belong to Pfizer Vaccine, although only 1.5 million doses of Moderna Booster have been distributed.

Some of these shots are unauthorized, being given during routine check-ups by primary care physicians and other doctors.

Moderna, based in Cambridge, Massachusetts, is now pushing to distribute its boosters as widely as Pfizer, and has expanded eligibility.

Moderna’s booster shot will be discussed by an FDA advisory panel on Thursday.

Booster shots for the Moderna vaccine were expected to roll out on September 20 to all Americans age 18 or older.

The White House announced in late August that both Pfizer and Moderna Vaccines would have boosters available in late September, pending approval from regulators such as the FDA.

Despite the declining effectiveness of vaccines, injections are still considered effective in preventing hospitalization or death.

Because of this, regulators did not approve the shots until the September 20 deadline, and even when the Pfizer booster was finally authorized, it did not receive full approval for all Americans, aimed at White. House was.

Meanwhile, J&J only makes the one-shot vaccine available in the US, and is hoping to receive authorization for other shots later this week.

The company reports some rare side effects such as blood clotting or swelling in the heart in people receiving the booster, but not to the extent that it believes the shot is unsafe.

Authorization for second shots of J&K vaccine will be discussed by the advisory panel on Friday.

J&J and Moderna COVID-19 vaccine initial regimen available to all adults in the US

The Pfizer vaccine — unlike the other two — is also available for minors between the ages of 12 and 17.

More than 150 million doses of the two-shot Moderna vaccine have been used in the US since the shot was authorized in December — Pfizer trailing the shot by 80 million — and Johnson & Johnson administered 15 million doses. Has been.

Nationwide, 65 percent of Americans have received at least one dose of a COVID vaccine, and 56 percent are fully vaccinated.

Booster shots are not yet included in the definition of ‘fully vaccinated’, so anyone who receives two shots of Pfizer or Moderna or one shot of J and J is fully vaccinated.

.

- Advertisement -
Mail Us For  DMCA / Credit  Notice

Recent Articles

Stay on top - Get the daily news in your inbox

Related Stories